AMY-101 acetate - KKL Med Inc.

您当前的位置：

AMY-101 acetate

目录号 : KM14304 纯度 : 98%

Data Sheet 产品使用指南

AMY-101 acetate (Cp40 acetate) 是补体 C3 的肽类抑制剂 (K_D = 0.5 nM)，可抑制非人类灵长类动物自然发生的牙周炎。AMY-101 acetate (Cp40 acetate) 在 COVID-19 重症肺炎合并全身超炎症模型中具有良好的抗炎活性。

规格	价格	是否有货
1mg		In-stock
5mg		In-stock
10mg		In-stock
50mg	询价	In-stock
100mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

(Tyr0)-Urocortin, rat In-stock
Stressin I In-stock
Suc-AAA-pNA In-stock
Perfluoropolyether carboxylic acid In-stock
Ala-D-γ-Glu-Lys-D-Ala-D-Ala In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K_D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.

体内研究

AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis.
AMY-101 can induce a long-lasting anti-inflammatory effect.
AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction.
AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis.

Animal Model:	Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight).
Dosage:	0.1 mg/site; 50 μL of 2 mg/mL solution.
Administration:	Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.)
Result:	Does not cause irritation in healthy gingiva.

Animal Model:	UUO and sham-operated mice.
Dosage:	1 mg/kg.
Administration:	Subcutaneous injection every 12 h, daily, 7 or 14 days.
Result:	1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (54.08 mM; Need ultrasonic)

H₂O : 50 mg/mL (27.04 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.5408 mL	2.7039 mL	5.4079 mL
5 mM	0.1082 mL	0.5408 mL	1.0816 mL
10 mM	0.0541 mL	0.2704 mL	0.5408 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (1.35 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.35 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (1.35 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (1.35 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (1.35 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.35 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。